Reviva Pharmaceuticals Advances Novel Treatment for Schizophrenia

Reviva Pharmaceuticals Inc. has made significant progress in the development of a novel drug aimed at treating schizophrenia, a complex brain disorder affecting approximately 24 million people worldwide, including 3.7 million in the United States. Current treatments primarily focus on alleviating hallucinations and delusions but often fail to address negative symptoms such as diminished motivation and social withdrawal. This limited efficacy can lead to patient nonadherence, particularly as around 30% of schizophrenia patients do not respond to existing medications.

The company’s candidate, brilaroxazine, represents a new class of multimodal neuromodulators designed to combat both the neurotransmitter imbalances associated with schizophrenia and the neuroinflammation that often accompanies it. This innovative approach could potentially transform treatment for the estimated 1.1% of the global population diagnosed with the condition.

Innovative Treatment Mechanism

Brilaroxazine operates by modulating serotonin and dopamine receptors in the brain. It functions as both a partial agonist and antagonist, aimed at stabilizing the serotonin-dopamine system that plays a crucial role in schizophrenia and related neuropsychiatric disorders. The drug is administered once daily, making it a convenient option for patients.

Reviva Pharmaceuticals has successfully completed two large-scale clinical trials—the Phase 2 and Phase 3 trials—along with a long-term open-label extension (OLE) study. These trials have shown sustained efficacy over a one-year period, with significant reductions in scores on the Positive and Negative Syndrome Scale (PANSS), which evaluates the major symptoms of schizophrenia. Notably, the findings indicated a well-tolerated safety profile, with minimal discontinuation rates and no major adverse events linked to the drug.

According to Reviva, the treatment has demonstrated its potential to improve the quality of life for patients, especially those who are treatment-refractory. Importantly, there were no reports of common side effects associated with current antipsychotics, such as motor dysfunction or metabolic complications.

Regulatory Path Forward

The long-term data collected from the OLE trial is crucial for Reviva as it prepares to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). This application is a formal request for approval to market brilaroxazine in the United States. Reviva anticipates a pre-NDA meeting with the FDA in Q4 2025, with plans to submit the NDA in Q2 2026. The outcomes of these regulatory steps could serve as significant catalysts for the company’s future.

Brilaroxazine is not only positioned as a potential new standard of care for schizophrenia but may also be expanded to address other conditions such as bipolar disorder, major depressive disorder, and attention deficit hyperactivity disorder. The aggregate market for these psychiatric conditions is projected to exceed $50 billion by 2030, highlighting the commercial significance of Reviva’s advancements.

As Reviva Pharmaceuticals continues to navigate the regulatory landscape, the promising results from its clinical trials suggest that brilaroxazine could be a game-changer in the treatment of schizophrenia and related disorders. The company remains a key player to watch in the pharmaceutical industry as it seeks to address unmet medical needs for millions affected by these challenging conditions.